

*Disclaimer :*

*The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.*

**M.7277 – ELI LILLY / NOVARTIS ANIMAL HEALTH**

**SECTION 1.2**

**Description of the concentration**

- (1) This notification concerns Eli Lilly and Company's (USA) proposed acquisition of the business of Novartis Animal Health ("NAH") from Novartis AG (Switzerland).
- (2) The business activities of the parties are:
  - *Eli Lilly*: discovery, development, manufacture and sale of a range of pharmaceutical products for humans and animals.
  - *NAH*: discovery, manufacturing, development and sale of animal health products to prevent and treat diseases in companion animals, production animals and farmed fish.